Published in Women's Health Weekly, August 25th, 2005
The deal terms included $209.25 million cash and additional non-cash consideration.
The acquired products include the Darvon and Darvocet brand families, Oramorph SR, Methadone Injection, Duraclon, Roxicodone, and Roxanol, as well as 4 new products in development. Xanodyne already has a solid presence in the women's health arena with its currently marketed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly